University of Pennsylvania drives new discoveries in cancer immunotherapy research on an international scale, and pioneered the first FDA-approved CAR-T cell therapy. Penn’s award-winning doctors and scientists focus on training immune cells to recognize and hunt cancer cells. PICI at Penn extends this work and supports laboratory studies and clinical trials, recruitment of talented new faculty and opportunities for early-career investigators who will train at Penn. Carl June, MD | Director E. John Wherry, PhD | Co-Director All Investigators Related Our Impact, Press Release, Research Update For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size Clinical Trial The PRINCE Trial Research Update A Bubble of Hope for Cancer: the Exosome in Immunotherapy Press Release Parker Institute researchers publish first major scientific paper in Nature Announcement, Press Release First Patients Dosed in Pancreatic Platform Trial Partner Highlight Connecting Patients with Innovative Immunotherapies Our Impact, Partner Highlight All the Right Ingredients: The Founders of ArsenalBio Partner Highlight, Press Release NanoString and PICI Partner to Optimize Cell Therapies Announcement, Research Update Five Key Takeaways from ASCO 2021
Our Impact, Press Release, Research Update For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size